Elutia Inc. (ELUT) Fair Value 2026

ELUT · Medical Devices ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.2 /10

32 fundamental signals · 1 models active

Value Trap Risk

WARN (56/100)

Quick Summary — As of 2026-08-28, Elutia Inc. (ELUT) trades at $0.88. QOC: 5.2/10. Value Trap Risk: 56/100 (WARN). 1/13 models active.

Key Facts

Ticker
ELUT
Price
$0.88
Quality Score
5.2/10
Value Trap Risk
56/100
Models Active
1/13
Last Updated
Strength: 1 independent models provide multi-angle coverage
Risk: Value Trap score of 56 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give ELUT?

1 Intrinsic Value Models vs. Current Price ($0.88)

Core Models (Unlocked)
Model Fair Value Upside
Option-Based · Low Conviction
 $0.66 -25.1%

All Models Active

All 1 models are displayed above.

What Is Elutia Inc. (ELUT) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Elutia Inc.'s intrinsic value is estimated at $0.66. Trading at its current price of $0.88, the valuation engine raises significant caution: 1 of 1 models flag downside risk, projecting a median implied return of -25.1%.

What Do the Models Say About ELUT?

1 of 13 models are currently active for ELUT. All 1 active models suggest the stock trades above fair value. See which stocks rank higher →

How Does ELUT Rank in Medical Devices?

Among 159 Medical Devices stocks, ELUT ranks #119 by Quality of Company score. CirclFi's QOC score of 5.2/10 evaluates 32 fundamental signals. A score of 5.2 reflects mixed fundamentals.

See all Most Undervalued Medical Devices Stocks →

The Medical Devices sector introduces analytical considerations specific to biopharma enterprise businesses. For Elutia Inc., metrics like pipeline depth and stage distribution provide important context that general-purpose valuation models may underweight.

Is ELUT a Value Trap?

CirclFi's Value Trap algorithm assigns ELUT a score of 56/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Elutia Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Elutia Inc. scores 5.2 out of 10 on our 32-signal quality assessment, a moderate rating that shows mixed signals across our quality framework with notable weaknesses. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every ELUT valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across ELUT's 1 active models, average confidence is 16%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Elutia Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Devices Stocks Should You Also Analyze?

11 related Medical Devices stocks with 13-model coverage

IRIXIRIDEX CorporationQOC 5.2CTSOCytosorbents CorporationQOC 5.2NUWENuwellis, Inc.QOC 5.3CATXPerspective Therapeutics, Inc.QOC 5.2QSIQuantum-Si incorporatedQOC 5.4MDAISpectral AI, Inc.QOC 5.1BWAYBrainsWay Ltd.QOC 2.6SRTSSensus Healthcare, Inc.QOC 7.3AHCOAdaptHealth Corp.QOC 6.3IRMDIRADIMED CORPORATIONQOC 9.8PODDInsulet CorporationQOC 9.6

Read investment analysis: IRIX · CTSO · NUWE · CATX · QSI · MDAI · BWAY · SRTS · AHCO · IRMD · PODD

Which Other Stocks Have a Similar Quality Score to ELUT?

6 companies across all industries closest to ELUT’s Quality of Company score of 5.2/10.

DAREDaré Bioscience, Inc.QOC 5.2LEELee Enterprises, IncorporatedQOC 5.2CBUSCibus, Inc.QOC 5.2GRHIGold Rock Holdings, Inc.QOC 5.2NAASNaaS Technology Inc.QOC 5.2NVDANVIDIA CorporationQOC 10.0

Read investment analysis: DARE · LEE · CBUS · GRHI · NAAS · NVDA

Where Does ELUT Sit in CirclFi's Medical Devices Rankings?

ELUT is ranked against every other Medical Devices stock CirclFi covers in each of these screens.

See all Medical Devices stocks ranked →

What Else Do Investors Ask About Elutia Inc.’s Valuation?

What is Elutia Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Elutia Inc. (ELUT). The Quality of Company score is 5.2/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is ELUT overvalued or undervalued right now?

At $0.88, 0 of 1 active models suggest ELUT may be undervalued, while 1 indicate potential overvaluation. The assessment depends on which methodology best fits Elutia Inc.'s business model in Medical Devices.

What does a Quality of Company score of 5.2 mean for ELUT?

Elutia Inc.'s QOC of 5.2/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on ELUT?

CirclFi analyzes ELUT with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is ELUT a value trap in 2026?

Elutia Inc.'s Value Trap score is 56/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Elutia Inc. (ELUT) a Quality of Company score of 5.2/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/ELUT/ · Methodology
Primary sources for this ELUT valuation
  • Financial statements: Elutia Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001708527) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for ELUT as of ; valuations recomputed .